Precision Medicine in Oncology® | Specialty

BRCA Screening Recommendations by Geneticist Mary-Claire King

October 1st 2014

Latest News & Insight: October 1, 2014

October 1st 2014

EGFR Pioneer Keeps Focus on Individualizing Patient Care in Lab and Clinic

October 1st 2014

As director of the Yale Cancer Center and physician-in-chief of the Smilow Cancer Hospital at Yale-New Haven, Thomas J. Lynch Jr, MD, wears many hats. And, having built a career united around two abiding goals of clinical discovery and personalized patient care, that's just the way he likes it.

Dr. Ledermann Discusses Olaparib in Ovarian Cancer

October 1st 2014

Jonathan Ledermann, BSc, MD, FRCP, Professor of Medical Oncology in the UCL Cancer Institute, University College London, discusses health-related quality of life during olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation.

Expanded 80405 Study Mutation Analysis Fails to Resolve Targeted Therapy Quandary in mCRC

September 30th 2014

All patients with metastatic colorectal cancer should undergo RAS mutation testing to ensure optimal patient selection for EGFR inhibitor therapy.

Multiple Factors Impact BRCA Testing Decision

September 23rd 2014

More than one-third of patients with breast or ovarian cancer or a family history of those diseases who also saw a genetic counselor did not pursue genetic testing for BRCA 1 or BRCA 2 mutations.

Dr. Lazarus Discusses Companion Diagnostics

September 18th 2014

Tadd Lazarus, MD, Chief Medical Officer, QIAGEN, provides an overview of companion diagnostics.

Genetic Cancer Screening for All?: The Evolving BRCA1/BRCA2 Story

September 18th 2014

Numerous epidemiological factors affect the likelihood of developing breast and ovarian cancer, but no other predictor is as powerful as an inherited mutation in BRCA1 or BRCA2, genes involved in both tumor suppression and DNA repair.

Blood-Based Biomarkers Predict Outcomes Following Neoadjuvant Treatment in Esophageal Cancer

September 16th 2014

High pretreatment levels of serum VEGF-A and TGF-β1 indicated significantly worse disease-free survival (DFS) following neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.

Beyond the Clinical Trial

September 14th 2014

Oncologists Need Guideposts for Recommending Drugs Not Studied in Cancers

Urologists Discuss Their Use of Biomarker Tests in Considering Active Surveillance

September 12th 2014

Experts Touch On Oncotype DX, Other Assays During Peer Exchange

Molecular Era Tumor Boards: Team Approach to Interpreting Genomic Test Results Proves Valuable

September 11th 2014

How can a conscientious but very busy practitioner keep up with the massive quantity of molecular data that could potentially impact an individual patient with cancer? The Moores Cancer Center at the University of California, San Diego has updated the tumor board concept for the molecular era.

Beyond PSA: A Summary Review of Predictive/Prognostic Biomarkers in Prostate Cancer

September 11th 2014

Although prostate cancer (PC) is the most common solid tumor malignancy among men in the Western Hemisphere, disease-specific mortality remains low, primarily due to optimized screening, diagnosis, and treatment.

Dr. Yang Discusses the Future of Lung Cancer Treatment

September 10th 2014

James CH Yang, MD, PhD, from the National Taiwan University Hospital, discusses the future of lung cancer treatment.

Veliparib Active in Patients with BRCA-Positive Breast, Ovarian Tumors

September 6th 2014

The PARP inhibitor veliparib exhibits antitumor activity and is safe and tolerable on a continuous dosing schedule when used for the treatment of patients with BRCA-positive and BRCA-wild type tumors.

Patient-Derived Xenograft (PDX) Models as Avatars for Patient Response to Therapy

September 3rd 2014

The promise of personalized medicine in cancer will only be met once physicians have both the arsenal of therapeutics they need and a more complete understanding of genomic tumor profiles.

"Angelina Jolie Effect" Sparks More BRCA Testing at Cancer Center

September 2nd 2014

The actress Angelina Jolie's decision to undergo a preventive double mastectomy after learning she carried the BRCA1 gene mutation-associated with an increased risk of breast and/or ovarian cancer-apparently sparked an "Angelina effect" on public health.

Dr. Isaacs on the Importance of Genetic Counseling

September 2nd 2014

Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses the importance of genetic counseling and the role of the genetic counselor

Advaxis Scientific Officer Illuminates ADXS-PSA/Pembrolizumab Collaborative Study

August 30th 2014

Robert Petit, PhD, the chief scientific officer at Advaxis, provides insight into the ADXS-PSA immunotherapy and the rationale behind the combination study with pembrolizumab.

Molecularly Targeted Therapy and Immunotherapy: The Next Frontier in Metastatic Bladder Cancer

August 27th 2014

A major step toward improved tolerability of cisplatin-based therapy came in the early 2000s with the advent of the modern regimen of gemcitabine and cisplatin.